Novartis India Launches Pluvicto
Analysis based on 6 articles · First reported Jun 15, 2026 · Last updated Jun 16, 2026
The launch of Lutetium (177Lu) vipivotide tetraxetan by Novartis is expected to positively impact the pharmaceutical and healthcare markets in India by introducing an advanced treatment option for prostate cancer. This could lead to increased revenue for Novartis and potentially influence the stock performance of its parent company, Novartis, as it expands its global market presence in precision oncology.
Novartis has launched Lutetium (177Lu) vipivotide tetraxetan (lutetium (177Lu) vipivotide tetraxetan), the first regulatory authority-approved radioligand therapy in India for eligible patients with Prostate-Specific Membrane Antigen (PSMA)-positive metastatic prostate cancer. This new treatment aims to precisely target cancer cells, minimizing harm to healthy tissues. The launch addresses the growing burden of prostate cancer in India, where approximately 250,000 new cases are diagnosed annually, with about 50% presenting at a metastatic stage. Novartis plans to collaborate with healthcare institutions and nuclear medicine centers across India to ensure access to Lutetium (177Lu) vipivotide tetraxetan, leveraging the country's expanding nuclear medicine infrastructure. This initiative is part of Novartis' broader strategy to bring globally approved innovations to priority markets like India.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard